The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).
Ernst M, Alaiwi S, Dizman N, Labaki C, Nuzzo P, Adib E, Schmidt A, Meza L, Gan C, Wells J, Bakouny Z, Pal S, Choueiri T, Heng D, Dudani S. The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT). Journal Of Clinical Oncology 2021, 39: 4552-4552. DOI: 10.1200/jco.2021.39.15_suppl.4552.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsOverall survivalABS exposureClinical outcomesTreatment failureResponse rateMultivariable analysisIndependent associationRisk factorsAdministration of AbFourth-line settingIMDC risk factorsIMDC risk scoresPoor-risk diseaseTreatment linesMultivariable Cox regressionInferior clinical outcomesInferior overall survivalIndependent prognostic markerRenal cell carcinomaSignificant independent associationOutcomes of interestIMDC criteriaCheckpoint inhibitors